Published in Drug Metab Pharmacokinet on April 01, 2006
Grapefruit-medication interactions: forbidden fruit or avoidable consequences? CMAJ (2012) 1.84
Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol (2010) 1.20
Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study. Eur J Clin Pharmacol (2009) 0.95
Tacrolimus severe overdosage after intake of masked grapefruit in orange marmalade. Eur J Clin Pharmacol (2007) 0.84
Different influences on tacrolimus pharmacokinetics by coadministrations of zhi ke and zhi shi in rats. Evid Based Complement Alternat Med (2011) 0.77
Hidden sources of grapefruit in beverages: potential interactions with immunosuppressant medications. Hosp Pharm (2013) 0.75
Nonalcoholic steatohepatitis in donors for living donor liver transplantation. Transplantation (2007) 2.25
Living donor liver transplantation: the Asian perspective. Transplantation (2014) 2.13
Impact of human leukocyte antigen mismatching on outcomes of living donor liver transplantation for primary biliary cirrhosis. Liver Transpl (2007) 2.09
Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol (2007) 2.05
Portal pressure <15 mm Hg is a key for successful adult living donor liver transplantation utilizing smaller grafts than before. Liver Transpl (2010) 2.02
Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet (2005) 1.96
Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol (2002) 1.85
Does a positive lymphocyte cross-match contraindicate living-donor liver transplantation? Surgery (2010) 1.82
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol (2009) 1.82
Single center experience of 39 patients with preoperative portal vein thrombosis among 404 adult living donor liver transplantations. Liver Transpl (2006) 1.81
Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol (2006) 1.80
Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem (2002) 1.79
Auxiliary partial orthotopic living donor liver transplantation: Kyoto University experience. Am J Transplant (2005) 1.70
SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol (2009) 1.70
Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl (2012) 1.67
Left-sided grafts for living-donor liver transplantation and split grafts for deceased-donor liver transplantation: their impact on long-term survival. Clin Res Hepatol Gastroenterol (2011) 1.63
Living donor liver transplantation with reduced monosegments for neonates and small infants. Transplantation (2007) 1.61
Comprehensive and innovative techniques for liver transplantation in rats: a surgical guide. World J Gastroenterol (2010) 1.57
Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol (2009) 1.53
Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther (2006) 1.52
Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl (2006) 1.52
Noninvasive evaluation of graft steatosis in living donor liver transplantation. Transplantation (2004) 1.49
Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res (2004) 1.49
Dai-kenchu-to attenuates rat sinusoidal obstruction syndrome by inhibiting the accumulation of neutrophils in the liver. J Gastroenterol Hepatol (2009) 1.48
Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl (2006) 1.48
Anatomical variations and surgical strategies in right lobe living donor liver transplantation: lessons from 120 cases. Transplantation (2002) 1.48
Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. J Nutr (2010) 1.47
Long-term quality of life of donors after living donor liver transplantation. Liver Transpl (2012) 1.47
Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol (2011) 1.47
Pre- and perioperative factors affecting infection after living donor liver transplantation. Nutrition (2012) 1.46
Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. Liver Transpl (2003) 1.46
Changes in portal venous pressure in the early phase after living donor liver transplantation: pathogenesis and clinical implications. Transplantation (2003) 1.45
Living-donor liver transplantation with monosegments. Transplantation (2003) 1.45
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol (2012) 1.43
Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. Am J Physiol Cell Physiol (2008) 1.38
Is MIBG a substrate of P-glycoprotein? Eur J Nucl Med Mol Imaging (2006) 1.37
Duct-to-duct biliary reconstruction in living donor liver transplantation utilizing right lobe graft. Ann Surg (2002) 1.37
Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol (2007) 1.35
Biliary reconstruction in right lobe living-donor liver transplantation: Comparison of different techniques in 321 recipients. Ann Surg (2006) 1.35
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol (2010) 1.34
C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics (2002) 1.33
Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University. Liver Transpl (2005) 1.32
Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res (2007) 1.32
Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria Type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B. Hum Mutat (2011) 1.31
Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol (2005) 1.28
Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl (2007) 1.27
Maternal microchimerism in underlying pathogenesis of biliary atresia: quantification and phenotypes of maternal cells in the liver. Pediatrics (2008) 1.27
Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A (2004) 1.27
CTRP9 protein protects against myocardial injury following ischemia-reperfusion through AMP-activated protein kinase (AMPK)-dependent mechanism. J Biol Chem (2012) 1.26
An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther (2006) 1.22
Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther (2006) 1.20
Small-for-size graft in living donor liver transplantation: how far should we go? Liver Transpl (2003) 1.19
Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther (2009) 1.18
Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery (2013) 1.17